GC
Therapeutic Areas
AAVogen Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AVGN7 | Inclusion Body Myositis (IBM) | Pre-clinical |
| AVGN7 + AVGND | Duchenne Muscular Dystrophy (DMD) | Pre-clinical |
Leadership Team at AAVogen
B"
Buel "Dan" Rodgers, PhD
Founder & CEO
AM
Alexandra McPherron, PhD
Chief Scientific Officer (CSO)
JB
Jade Brown, MBA
Business Development Director
CN
Chris Novashinski
Regulatory Affairs Director, Co-Founder & COO (RareMoon)
JR
Joseph Rininger, PhD
CMC Director